Entrada Therapeutics
TRDA | NASDAQ
$5.00
-$0.09 (-1.77%)
At close: Nov 16, 2026, 4:00 PM ET
$5.07
+$0.07 (+1.40%)
After-hours:
Nov 16, 2026, 4:39 PM ET
-1.77%
(1D)No price chart data available for 1D timeframe.
Rating
32.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #744/1021 (Top 73%)
Key Statistics
Market Data
Market Cap $211.87M
1D Range
4.84 5.22
52W Range
4.37 16.03
Valuation (TTM)
PE -1.30
PB 1.07
EV/EBITDA -0.41
Valuation (NTM)
Forward PE N/A
Forward PEG -0.16
Price Target $14.00
Cash Flow
FCF Yield -64.3%
SBC Adj. FCF Yield -73.3%
SBC Impact -14.0%
Margins
Gross Margin 57.5%
Operating Margin -4303.8%
FCF Margin -3428.1%
Growth (CAGR)
Revenue 3Y | 5Y -64.3% |
-2.4%
Dil EPS 3Y | 5Y -171.8% |
-20.5%
FCF 3Y | 5Y -62.9% |
-63.2%
Returns
ROA -60.5%
ROE -64.0%
ROIC -69.7%
Financial Health
Net Cash
$193.02M
Current Ratio 7.85
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Entrada Therapeutics, Inc. operates as a biotechnology enterprise dedicated to pioneering endosomal escape vehicle (EEV) therapeutics, specifically engineered to tackle a range of neuromuscular ailmen...
Sector Healthcare
Industry Biotechnology
Employees 152
IPO Date Oct 29, 2021
Website www.entradatx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 5, 2026
EPS
-$0.94
Beat +6.93%
YoY:
+11.32% REV
$905K
Miss -60.58%
YoY:
-43.93%Next Earnings
Feb 25, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
3
Consensus
Buy
Price Target
$14.00
Upside
+180.00%
Buy (2)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove TRDA